首页> 外文OA文献 >Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

【2h】

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

机译：维拉非尼在BRAF（V600E）和BRAF（V600K）突变阳性黑色素瘤（BRIM-3）中的安全性和有效性：扩展的3期随机，开放标签研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
McArthur, Grant A; Chapman, Paul B; Robert, Caroline; Larkin, James; Haanen, John B; Dummer, Reinhard; Ribas, Antoni; Hogg, David; Hamid, Omid; Ascierto, Paolo A; Garbe, Claus; Testori, Alessandro; Maio, Michele; Lorigan, Paul; Lebbé, Celeste; Jouary, Thomas; Schadendorf, Dirk; O'Day, Stephen J; Kirkwood, John M; Eggermont, Alexander M; Dréno, Brigitte; Sosman, Jeffrey A; Flaherty, Keith T; Yin, Ming; Caro, Ivor; Cheng, Suzanne; Trunzer, Kerstin; Hauschild, Axel;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study [J] . McArthurG.A., ChapmanP.B., RobertC., The lancet oncology . 2014,第3期

机译：维拉非尼在BRAFV600E和BRAFV600K突变阳性黑色素瘤（BRIM-3）中的安全性和有效性：扩展的3期随机，开放标签研究
2. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma [J] . GrippoJ.F., ZhangW., HeinzmannD., Cancer chemotherapy and pharmacology. . 2014,第1期

机译：维拉非尼在BRAF V600E突变阳性转移性黑色素瘤患者中的多剂量药代动力学的I期随机，开放标签研究
3. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis [J] . Blank Christian U., Larkin James, Arance Ana M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：3219例BRAF（V600）突变阳性转移性黑素瘤的vemurafenib的开放标签，vemurafenib的多期安全研究：2年后续数据和长期响应者分析
4. An open-label, multicenter, randomized,comparative, safety, efficacy, cycle control,and quality of life study of CTR 25, Alesse ,and Ortho Tri-Cyclen [C] . Victoria Davis, Brian Hauck, Sheila Dunn, World Congress on Fertility and Sterility . 2004

机译：开放标签，多中心，随机，比较，安全，疗效，循环控制和CTR 25，Alesse和Ortho Tri-Cyclen的生命研究
5. Development of Nanoliposomes for the Treatment of Braf V600e Mutated Parent and Vemurafenib-Resistant Melanoma [D] . Fu, Yige. 2021

机译：用于治疗BRAF V600E突变父母和vemureafenib抗性黑素瘤的纳米脂质体的研制
6. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3 randomised open-label study [O] . Prof. Grant A McArthur, Prof. Paul B Chapman, Caroline Robert, -1

机译：维拉非尼在BRAFV600E和BRAFV600K突变阳性黑色素瘤（BRIM-3）中的安全性和有效性：扩展的3期随机开放标签研究
7. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study [O] . Garbe, Claus 2014

机译：维拉非尼在BRAF（V600E）和BRAF（V600K）突变阳性黑色素瘤（BRIM-3）中的安全性和有效性：扩展的3期随机，开放标签研究

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

著录项

相似文献

相关主题

期刊订阅